Novartis AG (NVS) Stake Lifted by Moors & Cabot Inc.
Moors & Cabot Inc. lifted its position in Novartis AG (NYSE:NVS) by 7.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 41,223 shares of the company’s stock after purchasing an additional 3,028 shares during the period. Moors & Cabot Inc.’s holdings in Novartis were worth $3,547,000 as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of the company. Cetera Advisors LLC boosted its holdings in Novartis by 16.0% in the third quarter. Cetera Advisors LLC now owns 6,197 shares of the company’s stock valued at $534,000 after acquiring an additional 856 shares in the last quarter. Yellowstone Partners LLC bought a new stake in Novartis in the third quarter valued at $584,000. Fieldpoint Private Securities LLC boosted its holdings in Novartis by 25.9% in the third quarter. Fieldpoint Private Securities LLC now owns 4,657 shares of the company’s stock valued at $400,000 after acquiring an additional 957 shares in the last quarter. Wealthcare Advisory Partners LLC bought a new stake in Novartis in the third quarter valued at $106,000. Finally, Marco Investment Management LLC boosted its holdings in Novartis by 3.2% in the third quarter. Marco Investment Management LLC now owns 28,801 shares of the company’s stock valued at $2,473,000 after acquiring an additional 906 shares in the last quarter. Hedge funds and other institutional investors own 10.87% of the company’s stock.
Shares of Novartis AG (NVS) traded up $0.20 during mid-day trading on Thursday, hitting $84.66. 879,300 shares of the stock were exchanged, compared to its average volume of 2,248,176. Novartis AG has a 1 year low of $69.53 and a 1 year high of $86.90. The company has a market cap of $199,798.16, a PE ratio of 17.78, a PEG ratio of 2.68 and a beta of 0.73. The company has a current ratio of 1.08, a quick ratio of 0.81 and a debt-to-equity ratio of 0.32.
Several research firms recently weighed in on NVS. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis in a report on Tuesday, September 26th. Zacks Investment Research cut shares of Novartis from a “buy” rating to a “hold” rating in a report on Thursday, September 21st. Leerink Swann boosted their target price on shares of Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. Bank of America cut shares of Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Finally, Barclays cut shares of Novartis from an “equal weight” rating to an “underweight” rating in a report on Wednesday, October 25th. Four equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $85.32.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.